Zhou Iris Wenyu, Zhang Anthony Lin, Tsang Miranda Sin-Man, Xue Charlie C
The China-Australia International Research Centre for Chinese Medicine, School of Health and Biomedical Sciences, STEM College, RMIT University, Bundoora, Victoria, Australia.
PLoS One. 2025 Apr 21;20(4):e0321393. doi: 10.1371/journal.pone.0321393. eCollection 2025.
This systematic review investigates the potential role of vitamin D supplement in alleviating pain associated with primary dysmenorrhea or endometriosis by analysing registered randomised controlled trials (RCTs).
We comprehensively searched the WHO International Clinical Trials Registry Platform to identify registered RCTs that assessed the effects of vitamin D supplement on pain outcomes in people with primary dysmenorrhea or endometriosis. The primary outcomes of interest were pain severity/intensity, pain duration, pain medication usage and pain-related outcome measurements.
Seven registered RCTs were included in this systematic review. These RCTs had diverse doses and treatment durations of vitamin D supplement used as intervention. They also had either high or some concerns of risk of bias, according to Cochrane risk of bias version 2 assessment. Substantial heterogeneities were generally observed across the seven RCTs. When measured using a validated tool visual analogue scale (VAS), pain severity was significantly lower at the end of treatment when compared with placebo (mean difference MD -1.12, 95% confidence interval [-2.16, -0.07], I2=81%, 5 studies, n = 308). This significant difference was observed in the primary dysmenorrhea RCTs, but not the endometriosis RCTs.
This systematic review identified vitamin D may reduce pain associated with primary dysmenorrhea, though a low certainty of evidence was available. Future studies that use standardised doses and treatment duration in accordance with the latest clinical practice guidelines are needed to explore any potential benefits vitamin D may have for people with these conditions.
本系统评价通过分析已注册的随机对照试验(RCT),探讨维生素D补充剂在减轻原发性痛经或子宫内膜异位症相关疼痛方面的潜在作用。
我们全面检索了世界卫生组织国际临床试验注册平台,以确定评估维生素D补充剂对原发性痛经或子宫内膜异位症患者疼痛结局影响的已注册RCT。感兴趣的主要结局是疼痛严重程度/强度、疼痛持续时间、止痛药物使用情况以及与疼痛相关的结局测量。
本系统评价纳入了7项已注册的RCT。这些RCT使用了不同剂量和治疗持续时间的维生素D补充剂作为干预措施。根据Cochrane偏倚风险第2版评估,它们存在高偏倚风险或某些偏倚风险问题。在这7项RCT中普遍观察到显著的异质性。当使用经过验证的视觉模拟量表(VAS)进行测量时,与安慰剂相比,治疗结束时疼痛严重程度显著降低(平均差值MD -1.12,95%置信区间[-2.16, -0.07],I²=81%,5项研究,n = 308)。这种显著差异在原发性痛经RCT中观察到,但在子宫内膜异位症RCT中未观察到。
本系统评价发现维生素D可能减轻原发性痛经相关疼痛,尽管证据的确定性较低。需要未来的研究按照最新临床实践指南使用标准化剂量和治疗持续时间,以探索维生素D对这些疾病患者可能具有的任何潜在益处。